HER2DX Test Uncovers Molecular Heterogeneity in HER2-Positive Ductal Carcinoma in Situ
A retrospective genomic analysis shows that HER2-positive ductal carcinoma in situ exhibits substantial transcriptomic heterogeneity despite uniform HER2 protein overexpression.

